A new drug to treat a rare inherited bone disorder that was developed by Alexion Pharmaceuticals and could cost up to 1.5 million pounds a year per patient has been cleared for limited use by Britain’s health cost watchdog. The National Institute for Health and Care Excellence (NICE), which had turned down Strensiq as too expensive in December, said on Thursday it had decided the drug could offer a lifeline for a handful of babies and young children. Strensiq costs 58.80 pounds per milligram, meaning it would cost 165,000 pounds a year for babies weighing up to 9 kg and as much as 1.5 million pounds for adults and young people up to 80 kg, NICE said.
See the original post:
UK okays Alexion drug costing up to 1.5 million pounds but wants price cut